Compass Therapeutics Starts Plan For $50 Million IPO

|
About: Compass Therapeutics, Inc. (CMPX), Includes: ABBV, AMGN, AZN, AZNCF, BMY, BMYMP, GLAXF, GSK, JNJ, LLY, MRK, NVS, NVSEF, PFE, RHHBF, RHHBY, RHHVF, SNY, SNYNF
by: Donovan Jones
This article is exclusive for subscribers.
Summary

Compass Therapeutics has filed to raise $50 million in an IPO.

The firm is advancing programs to treat various cancers, including Her2+ breast cancer.

CMPX has produced intriguing results in preclinical studies for its lead candidate.

Quick Take

Compass Therapeutics (CMPX) has filed to raise $50 million in an IPO of its common stock, according to an S-1 registration statement.

The firm is a clinical stage biopharma developing